Interview with Amit Mehta, Managing Director, S. Amit & Co
India has experienced tremendous growth in its chemical and pharmaceutical industries. Being active for many years in the industry now, how have you seen the market evolving? S. Amit has…
Address: 101-A Neelam Centre, 249-B Hind Cycle Road, Worli, Mumbai 400 030, India
Tel: +91 22 4001 3000
S. Amit Speciality Chemicals Pvt. Ltd. is a leading full-service Chemistry Solutions provider in India delivering products and services in the areas of speciality chemicals, intermediates and performance chemicals for diverse applications including pharmaceuticals, agrochemicals, polymers & plastics, and paints and coating.
Over the last six decades, the Company has transitioned from representing international laboratory chemical suppliers to marketing 1 or 2 steps of chemistries to supplying advanced intermediates and performance chemicals such as reducing agents, resolving agents, encapsulated catalysts, etc. Focussed on its broad-based relationships with both customers and suppliers, the objective has always been to add value to the chemical supply chain for both parties.
Today, as an integrated solutions provider, the S. Amit Group of Companies focuses on offering a full range of supply chain services including – representation of manufacturers, global and local sourcing, distribution, virtual manufacturing, and identifying problems and recommending innovative chemical solutions. This allows our customers and suppliers to effectively extract value from the supply chain based on their needs and the market situation.
In January 2011, S. Amit acquired Reaxa U.K., a company actively involved in developing and supplying encapsulated metal catalysts for synthetic organic chemistry.
Through its various group companies, the S. Amit Group provides
Indenting
Local Sales and Distribution
Exports
Virtual Manufacturing Services
Products and services are branded through the following group companies – S. Amit, Finorga,
Chem Amit, Perfo Chem and Brom Chem
The S. Amit Group also has a joint venture company, Diamines & Chemicals Ltd. that manufactures piperazine at its plant in Baroda, Gujarat.
India has experienced tremendous growth in its chemical and pharmaceutical industries. Being active for many years in the industry now, how have you seen the market evolving? S. Amit has…
KV Subramaniam, president of Reliance Life Sciences, a research-driven medical biotech with a fully integrated value chain that covers everything from research to manufacturing, comments on the firm’s unique positioning…
Suresh Pattathil wears two hats within India’s vast pharma ecosystem. Not only is he responsible for managing AbbVie India as its Managing Director and GM, he also advocates for broader…
In the latest blow to Indian pharma’s reputation, the European Medicines Agency (EMA) has recommended the suspension of marketing authorisations for a large number of generics tested by Indian CRO…
Director of the oldest and largest cancer centre in India, the Tata Memorial Hospital, C S Pramesh also heads up the National Cancer Grid (NCG), a nationwide network of over…
Over the course of his 40-year career, oncologist Dr Ramakant Deshpande has taken an active role in the evolution of cancer care in India and in 2017 he became the…
Ayushman Bharat, launched in 2018, is a monumental scheme addressing the lack of healthcare accessibility and affordability for over 500 million people in India. Dr Indu Bhushan, Ayushman Bharat’s inaugural…
India’s chemical industry is of vital importance to several industries, including pharmaceuticals, and exported USD 30.18 billion worth of products in 2022-23. Chemexcil’s Raghuveer Kini discusses his industry’s key role…
Pratima Reddy, GM at Merck Healthcare India reviews the importance of Merck’s Indian affiliate, discusses the recent reforms that have contributed both to improving patient access and to fostering foreign…
The Indian pharma industry has demonstrated spectacular growth based on its strength as a global generics manufacturer. Yet Indian pharma is not merely resting on its laurels. After shining through…
Sandeep Verma shares his journey of establishing Bayer’s consumer healthcare division in India and reflects on the challenges faced during the division’s inception amidst the COVID-19 pandemic, emphasizing the importance…
India’s pharma industry has big dreams. At the recent Annual Summit of Organisation of Pharmaceutical Producers of India (OPPI) the nation’s policymakers, academicians, industry leaders, innovators, and scientists gathered to…
Peter DeYoung shares the significance of Indian giant Piramal Pharma’s recent demerger from its parent company and its current strategic focus on organic growth, brownfield expansions, and “complex hospital generics.”…
See our Cookie Privacy Policy Here
